导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.89% | 1724/2676 |
| 近一周 | -1.07% | 875/3004 |
| 近一月 | -3.28% | 1253/2984 |
| 近一季 | -11.62% | 2129/2896 |
| 近半年 | -2.54% | 1225/2746 |
| 近一年 | -1.56% | 1634/2519 |
| 近两年 | 52.17% | 822/1796 |
| 近三年 | 34.65% | 498/1340 |
| 成立以来 | 49.17% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.52% 4158/4961 |
22.20% 1134/5312 |
- - |
- - |
| 2025 | 26.14% 1656/4813 |
2.57% 1329/3635 |
0.01% 2780/4076 |
25.13% 1415/4524 |
-1.73% 3003/4813 |
| 2024 | 17.87% 645/3463 |
-0.07% 1068/2808 |
1.11% 501/3014 |
18.82% 925/3129 |
-1.82% 1846/3463 |
| 2023 | -12.76% 1506/2656 |
1.50% 1562/2280 |
-1.49% 497/2385 |
-6.77% 1500/2515 |
-6.40% 1753/2655 |
| 2022 | -20.34% 964/2207 |
-17.79% 1262/1919 |
8.10% 392/2016 |
-15.41% 1284/2113 |
5.96% 405/2208 |
| 2021 | -2.36% 850/1822 |
-5.82% 959/1255 |
7.07% 703/1330 |
-7.52% 1057/1466 |
4.71% 319/1822 |
| 2020 | 44.18% 230/1250 |
-8.58% 622/1028 |
19.04% 313/1067 |
16.47% 151/1164 |
13.76% 332/1184 |
| 2019 | - - |
- - |
- - |
- - |
9.54% 222/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 平安粤港澳大湾区ETF VS. 长安沪深300非周期A(740101) |